Journal article

CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment

Clare Y Slaney, Pin Wang, Phillip K Darcy, Michael H Kershaw

CANCER DISCOVERY | AMER ASSOC CANCER RESEARCH | Published : 2018

Abstract

The redirection of T cells against tumors holds much promise for the treatment of cancer. Two main approaches for T-cell redirection involve their genetic modification with chimeric antigen receptors (CAR), or the use of recombinant proteins designated bispecific T-cell engagers (BiTE). These approaches have demonstrated dramatic effects in patients with hematologic cancers, although limited effect against solid cancers. Here, we review and compare the successes and challenges of these two types of immunotherapies, with special focus on their mechanisms, and discuss strategies to improve their efficacy against cancer.Significance: CAR and BiTE cancer therapies have generated much excitement,..

View full abstract

Grants

Awarded by Cure Cancer Australia


Awarded by National Health and Medical Research Council (NHMRC) of Australia


Awarded by National Breast Cancer Foundation (NBCF) of Australia


Awarded by Susan G. Komen


Awarded by National Natural Science Foundation of China


Funding Acknowledgements

This work was supported by grants from Cure Cancer Australia (1100199), the Peter MacCallum Cancer Centre Foundation, the National Health and Medical Research Council (NHMRC) of Australia (1103352 and 1132373), the National Breast Cancer Foundation (NBCF) of Australia (IIRS-18-064), and Susan G. Komen (16376637). P.K. Darcy and M.H. Kershaw were supported by NHMRC Senior Research Fellowships. C.Y. Slaney was supported by a postdoctoral fellowship from the NBCF. P. Wang was supported by grants from the National Natural Science Foundation of China (31470871, 81671566, and 31722019).